Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 55Specimen Handling 28Biopsy 28Magnetic Resonance Spectroscopy 26Paclitaxel 23Blood Specimen Collection 22Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8durvalumab 8Taxes 8Ipilimumab 8Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Angiogenesis Inhibitors × Tumor-Agnostic × 1 year × Clear all
NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡